600161.SH
天坛生物
SSE · Healthcare · Biotechnology · CN
CNY 11.94
−1.73%Year over year
Reported trailing growth
- Revenue
- -2.2%
- EBITDA
- —
- EBIT
- -32.4%
- EPS
- -34.5%
- Free cash flow
- +97.4%
- Operating cash flow
- +1167.0%
Forward estimates
Based on analyst estimates
- Revenue
- -26.2%
- EBITDA
- +4.6%
- EPS
- +17.9%
Three-year CAGR
- Revenue
- +13.1%
- EBITDA
- +12.7%
- EBIT
- +8.7%
- Net income
- +7.4%
- EPS
- +1.2%
- Free cash flow
- -7.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026